omniture
百奥赛图(北京)医药科技股份有限公司 Biosetu (Beijing) Pharmaceutical Technology Co. Ltd

Latest News

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BEIJING, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pha...

2022-05-24 08:00 2069

Biocytogen Enters into Antibody Agreement with Merck

BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen)...

2022-04-29 20:00 2498

Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene

BEIJING, April 8, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced tha...

2022-04-08 21:00 5230

Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany

BEIJING, March 28, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter r...

2022-03-28 21:30 1784

Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA

BOSTON and BEIJING, July 7, 2021 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Bio...

2021-07-07 16:41 1796

Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars

BEIJING, June 23, 2021 /PRNewswire/ -- Biocytogen , an international biote...

2021-06-23 17:02 1783